冠心病介入治疗中抗血小板药物的应用

Application of Antiplatelet Drugs in the Treatment of Coronary Heart Disease Intervention

目的:探讨低分子肝素在冠心病介入治疗中的临床应用价值。方法:选择我院进行冠状动脉介入手术的患者88例,随机分为观察组和对照组,对照组给予普通肝素抗凝,观察组给予低分子肝素抗凝,观察两组穿刺血肿发生情况及手术后两组不良心血管事件情况。结果:观察组股动脉穿刺局部的平均压迫止血时间及穿刺局部血肿发生情况与对照组比较,经统计学分析,差异有统计学意义(P<0.05)。观察组不良心血管事件发生率为7.14%,对照组不良心血管事件发生率26.19%,两组比较经统计学分析,差异有统计学意义(P<0.05)。结论:低分子肝素应用于冠心病介入治疗中其安全性和有效性优于普通肝素,值得在临床上大力推广使用。

Objective：To investigate the value of clinical application of the low molecular weight heparin intervention therapy in coronary heart disease.Methods：To choose 88 patients underwent coronary artery intervention operation from our institute, were randomly divided into observation group and control group;The control group was given ordinary heparin anticoagulant therapy, and the observation group was given low molecular weight heparin;Observed two groups of puncture hematoma and adverse cardiovascular events after operation.Results：The observation group of femoral artery puncture local average compression hemostasia time and local hematoma puncture were compared with control, statistical analysis, the difference was statistically significant （ P〈0.05 ）. The observation group adverse cardiovascular event occurrence rate is 7.14%, the control group of adverse cardiovascular events occurred in 26.19%, between two groups by statistical analysis, the difference was statistically significant （ P〈0.05 ）.Conclusion：Low molecular weight heparin in patients with coronary heart disease and its safety and effectiveness is superior to UFH, worthy of promotion in clinical use.